ANDA 216120, held by Am Regent. Atropine Sulfate.
As of Nov 16, 2026, ANDA 216120 (Atropine Sulfate), held by Am Regent, was first approved by FDA on May 26, 2022, with 0 approved supplements and 0 published complete response letters.
Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 26, 2022 | Original application | Approved |
| Atropine Sulfate0.4MG/ML (0.4MG/ML) · solution;intravenous | Atropine Sulfate | Rx |
| Atropine Sulfate1MG/ML (1MG/ML) · solution;intravenous | Atropine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters